ORLANDO, FL--(Marketwire - September 30, 2009) -
Galea Life Sciences, Inc., maker of
Nutraplete™ therapeutic drink mix and a pioneer in the field of
therapeutic nutrition, today announced that it has filed a Form 10
Registration statement with the U.S. Securities and Exchange Commission
(SEC) to register its Common shares with the SEC. The registration
statement will not become effective until 60 days after the filing date, or
at an earlier date as determined by the SEC.
The Company expects its Common stock to open trading on the Over the
Counter Bulletin Board (OTCBB) if and when it clears SEC comments on the
Form 10 and FINRA has accepted the Company's stock for quotation.
About Nutraplete™
Nutraplete™ Therapeutic Drink Mix is the first therapeutic nutritional
dietary supplement created specifically to help people living with
HIV/AIDS. This multi-nutritional, therapeutic "functional food" includes
pharmaceutical grade supplements that may provide health benefits by
addressing common nutritional deficiencies. Nutraplete™ is available by
prescription and currently approved for Medicaid reimbursement in New York
State, New Jersey, Connecticut, Illinois, Nevada and Washington State. The
company is currently seeking Medicaid approval for Nutraplete™ in
California, Florida, Pennsylvania, Maryland, Washington, D.C. and other
states. For more information: www.nutraplete.com
Nutraplete™ is distributed exclusively in the U.S. by Allion Healthcare,
Inc. (NASDAQ: ALLI) under its MOMS Pharmacy trade name. MOMS Pharmacy is a
specialty pharmacy that is focused exclusively on providing medications and
support services to people living with HIV/AIDS. Visit
www.momspharmacy.com.
About Galea Life Sciences, Inc.
Galea Life Sciences, Inc. focuses on the emerging field of advanced
nutritional supplements designed to support traditional medical treatments
and therapies, and specializes in the formulation, manufacturing, marketing
and distribution of innovative dietary supplements that benefit people
undergoing medical treatments and therapies. Nutraplete™ is its
introductory product.
Certain statements in this release constitute forward-looking statements or
statements which may be deemed or construed to be forward-looking
statements within the meaning of the Private Securities Litigation Reform
Act of 1995. The words "forecast," "project," "intend," "expect," "should,"
"would," and similar expressions and all statements, which are not
historical facts, are intended to identify forward-looking statements.
These forward-looking statements involve and are subject to known and
unknown risks, uncertainties and other factors which could cause the
Company's actual results, performance (finance or operating) or
achievements to differ from future results, performance (financing and
operating) or achievements expressed or implied by such forward-looking
statements.
Statements herein express management's beliefs and expectations regarding
future performance and are forward-looking and involve risks and
uncertainties, including, but not limited to, the ability to negotiate
outstanding prior debts of acquired companies; properly identify
acquisition partners; adequately perform due diligence; manage and
integrate acquired businesses; react to quarterly fluctuations in results;
raise working capital and secure other financing; respond to competition
and rapidly changing technology; deal with market and stock price
fluctuations; and other risks.
